Radiation-induced lung fibrosis after treatment of small cell carcinoma of the lung with very high-dose cyclophosphamide

Cancer. 1985 Jan 1;55(1):57-60. doi: 10.1002/1097-0142(19850101)55:1<57::aid-cncr2820550110>3.0.co;2-l.

Abstract

Twenty-five previously untreated patients with small cell carcinoma of the lung were treated with cyclophosphamide 160 to 200 mg/kg (with autologous bone marrow support) followed by radiotherapy (4000 cGy) to the primary site and mediastinum. No other treatment was given until relapse occurred. Nineteen patients were assessable at least 4 months after radiotherapy; of these, 15 (79%) developed radiologic evidence of fibrosis, which was symptomatic in 14 (74%). The time of onset of fibrosis was related to the volume of lung irradiated. A retrospective analysis was made of 20 consecutive patients treated with multiple-drug chemotherapy and an identical radiotherapy regimen as part of a randomized trial. Radiologic and symptomatic fibrosis was one half as frequent (35%) as in the high-dose cyclophosphamide group. Very high-dose cyclophosphamide appears to sensitize the lung to radiotherapy and promotes the production of fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Small Cell / therapy*
  • Combined Modality Therapy
  • Cyclophosphamide / adverse effects*
  • Cyclophosphamide / therapeutic use
  • Female
  • Humans
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Pulmonary Fibrosis / etiology*
  • Radiation Injuries / etiology
  • Radiation-Sensitizing Agents
  • Radiotherapy / adverse effects*

Substances

  • Radiation-Sensitizing Agents
  • Cyclophosphamide